Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laser Vision Centers, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Provider of laser vision correction equipment and support services is served with an administrative complaint and notice of opportunity for hearing by FDA's Center for Devices and Radiological Health relating to a March 1998 subpoena, LVC announces April 20. FDA action under administrative civil monetary procedures, launched April 4, proposes to assess civil monetary penalties totaling $5 mil. ($1 mil. for the company and each of four involved executives) for actions considered to have adulterated the devices. FDA's complaint relates to the company's use of "international" or "Bermuda cards" - electronic key card software enabling the use of the firm's excimer lasers to treat myopia cases beyond the range of FDA approval (greater than -6 diopters) prior to 1998. The company maintains that neither LVC nor other U.S. users of excimer lasers have used the cards since early 1998. Accordingly, LVC does not expect the action to have a material impact on the company. In 1996, the agency compelled Visx to modify software in its Star laser system so surgeons could not perform photorefractive keratectomy procedures on high myopia or astigmatism patients. Visx denies any knowledge of FDA's current actions

You may also be interested in...



Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Biden COVID-19 Plan Would Grow Domestic Manufacturing Base

The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.

People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel